Aerosolized Pulmonary Delivery of mRNA Constructs Attenuates Severity of Escherichia coli Pneumonia in the Rat
Nucleic Acid Therapeutics · 01.04.2023 · 33 (2) · 148-158
DOI: 10.1089/nat.2022.0049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 30.03.2023. Verfasst von Sean D McCarthy und 9 weiteren Autor:innen. Beteiligte Einrichtung: CÚRAM and Regenerative Medicine Institute, University of Galway, Galway, Ireland. Hauptthemen laut MEDLINE: Pneumonia, Respiratory Distress Syndrome. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Acute respiratory distress syndrome (ARDS), a rapid onset inflammatory lung disease with no effective specific therapy, typically has pathogenic etiology termed pneumonia. In previous studies nuclear factor-κB (NF-κB) inhibitor α super-repressor (IκBα-SR) and extracellular superoxide dismutase 3 (SOD3) reduced pneumonia severity when prophylactically delivered by viral vector. In this study, mRNA coding for green fluorescent protein, IκBα-SR, or SOD3 was complexed with cationic lipid, passed through a vibrating mesh nebulizer, and delivered to cell culture or directly to rats undergoing Escherichia coli pneumonia. Injury level was then assessed at 48 h. In vitro , expression was observed as early as 4 h in lung epithelial cells. IκBα-SR and wild-type IκBα mRNAs attenuated inflammatory markers, while SOD3 mRNA induced protective and antioxidant effects. In rat E. coli pneumonia, IκBα-SR mRNA reduced arterial carbon dioxide (pCO2) and reduced lung wet/dry ratio. SOD3 mRNA improved static lung compliance and alveolar-arterial oxygen gradient (AaDO2) and decreased bronchoalveolar lavage (BAL) bacteria load. White cell infiltration and inflammatory cytokine concentrations in BAL and serum were reduced by both mRNA treatments compared to scrambled mRNA controls. These findings indicate nebulized mRNA therapeutics are a promising approach to ARDS therapy, with rapid expression of protein and observable amelioration of pneumonia symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CÚRAM and Regenerative Medicine Institute, University of Galway, Galway, Ireland.
- Factor Bioscience Ltd., Cambridge, Massachusetts, USA.
- Aerogen Ltd., Galway, Ireland.
ORCID-Profile: Sean D McCarthy, Ronan MacLoughlin
Zitieren
APA
McCarthy, S. D., Rohde, C. B., Angel, M., Masterson, C. H., MacLoughlin, R., Fandiño, J., González, H. E., Byrnes, D., Laffey, J. G., & O'Toole, D. (2023). Aerosolized Pulmonary Delivery of mRNA Constructs Attenuates Severity of Escherichia coli Pneumonia in the Rat. Nucleic Acid Therapeutics, 33(2), 148-158. https://doi.org/10.1089/nat.2022.0049
Vancouver
McCarthy SD, Rohde CB, Angel M, Masterson CH, MacLoughlin R, Fandiño J, et al. Aerosolized Pulmonary Delivery of mRNA Constructs Attenuates Severity of Escherichia coli Pneumonia in the Rat. Nucleic Acid Therapeutics. 2023;33(2):148-158. doi:10.1089/nat.2022.0049
BibTeX
@article{McCarthy2023,
author = {McCarthy, Sean D and Rohde, Christopher B and Angel, Matt and Masterson, Claire H and MacLoughlin, Ronan and Fandiño, Juan and González, Héctor E and Byrnes, Declan and Laffey, John G and O'Toole, Daniel},
title = {Aerosolized Pulmonary Delivery of mRNA Constructs Attenuates Severity of Escherichia coli Pneumonia in the Rat},
journal = {Nucleic Acid Therapeutics},
year = {2023},
volume = {33},
number = {2},
pages = {148--158},
doi = {10.1089/nat.2022.0049}
}
EUVIMED